Hybridan

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Your Partner for Growth

Your Partner for Growth, Hybridan

Equity Bottom-Up

<ul><li>The toxicology studies program for its lead TYK2/JAK1 inhibitor, SDC-1801, are starting.</li><li> In 2024, SDC-1801 which is a dual inhibitor targeting autoimmune diseases, completed Phase 1 clinical trials in healthy volunteers which demonstrated a favorable safety and pharmacokinetic profile.</li><li> These toxicology studies are the next key regulatory milestone on the pathway to a Phase 2 development programme.</li></ul>

The toxicology studies program for its lead TYK2/JAK1 inhibitor, SDC-1801, are starting. In 2024, SDC-1801 which is a dual inhibitor targeting autoimmune diseases, completed Phase 1 clinical trials in healthy volunteers which demonstrated a favorable safety and pharmacokinetic profile. These toxicology studies are the next key regulatory milestone on the pathway to a Phase 2 development programme.

Hybridan Research: Sareum Holdings plc: Significant Stepping Stone